Jiang Zhong PharmaceuticalLtd Management
Management criteria checks 3/4
Jiang Zhong PharmaceuticalLtd's CEO is Wenbin Xiao, appointed in Mar 2022, has a tenure of 2.75 years. directly owns 0.015% of the company’s shares, worth CN¥2.14M. The average tenure of the management team and the board of directors is 4.8 years and 1.1 years respectively.
Key information
Wenbin Xiao
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.8yrs |
| Board average tenure | 1.1yrs |
Recent management updates
Recent updates
Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) Analysts Just Slashed This Year's Revenue Estimates By 11%
Sep 12
Lacklustre Performance Is Driving Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E
Jul 20A Look At The Fair Value Of Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750)
May 22Why Investors Shouldn't Be Surprised By Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E
Apr 15CEO
Wenbin Xiao (44 yo)
2.8yrs
Tenure
CN¥1,408,800
Compensation
Mr. Wenbin Xiao serves as General Manager at Jiang Zhong Pharmaceutical Co.,Ltd since March 23, 2022. Mr. Wenbin Xiao served as Deputy General Manager at Jiang Zhong Pharmaceutical Co., Ltd., He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| General Manager | 2.8yrs | CN¥1.41m | 0.015% CN¥ 2.1m | |
| Financial Controller & Financial Director | 4.8yrs | CN¥709.70k | 0.011% CN¥ 1.6m | |
| Secretary of the Board of Directors | 9.6yrs | CN¥541.60k | 0.011% CN¥ 1.6m |
4.8yrs
Average Tenure
42yo
Average Age
Experienced Management: 600750's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.3yrs | no data | 0.035% CN¥ 4.9m | |
| Director | 2.1yrs | no data | no data | |
| Independent Director | 6yrs | CN¥93.30k | no data | |
| Director | 1.1yrs | no data | no data | |
| Independent Director | 4.6yrs | no data | 0.034% CN¥ 4.7m | |
| Director | 2.4yrs | no data | 0.029% CN¥ 4.1m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Chairman of Supervisory Board | 1.1yrs | no data | no data | |
| Supervisor | 1.1yrs | no data | no data | |
| Employee Supervisor | 1.1yrs | no data | no data |
1.1yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 600750's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 23:04 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiang Zhong Pharmaceutical Co.,Ltd is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Wang | BOCI Research Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Shanshan Li | China Merchants Securities Co. Ltd. |